📊 PLX Key Takeaways
Is Protalix BioTherapeutics, Inc. (PLX) a Good Investment?
Protalix faces severe operational headwinds with declining revenue (-1.2% YoY), devastating profitability metrics (0.4% gross margin, -12.5% net margin), and unsustainable cash burn of $12M annually against only $14.7M in cash reserves, implying ~1.2 years of runway. Despite minimal leverage and adequate liquidity ratios, the company's deteriorating commercial performance and inability to generate positive cash flow from operations present existential risk without significant operational improvement or capital infusion.
Why Buy Protalix BioTherapeutics, Inc. Stock? PLX Key Strengths
- Very low leverage with minimal debt burden (Debt/Equity: 0.02x, only $912K long-term debt)
- Healthy short-term liquidity ratios (Current: 2.51x, Quick: 1.54x) provide near-term operational flexibility
- Meaningful asset base of $82.3M and positive stockholders' equity of $48.2M provide some balance sheet cushion
PLX Stock Risks: Protalix BioTherapeutics, Inc. Investment Risks
- Revenue decline of 1.2% YoY in biotech sector indicates failing commercialization and market demand
- Catastrophic cash burn: $12M operating outflow annually with only $14.7M cash (approximately 1.2 years runway)
- Unsustainable profitability: 0.4% gross margin suggests severe production/pricing dysfunction; -10.4% operating margin indicates operational losses are structural not cyclical
- No insider purchases in 90 days suggests management lacks confidence in turnaround prospects
- Free cash flow of -$13.6M combined with declining revenue creates urgent financing needs
Key Metrics to Watch
- Quarterly revenue trend and sequential growth rate (current decline trajectory is critical)
- Gross margin improvement (0.4% is abnormally low and unsustainable)
- Operating cash flow burn rate and months of cash runway remaining
- Pipeline development progress and regulatory milestones for product development
- Capital raising activities and dilution impact from equity financing needs
Protalix BioTherapeutics, Inc. (PLX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.51x current ratio provides a solid financial cushion.
PLX Profit Margin, ROE & Profitability Analysis
PLX vs Healthcare Sector: How Protalix BioTherapeutics, Inc. Compares
How Protalix BioTherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Protalix BioTherapeutics, Inc. Stock Overvalued? PLX Valuation Analysis 2026
Based on fundamental analysis, Protalix BioTherapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Protalix BioTherapeutics, Inc. Balance Sheet: PLX Debt, Cash & Liquidity
PLX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Protalix BioTherapeutics, Inc.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $0.09 reflects profitable operations.
PLX Revenue Growth, EPS Growth & YoY Performance
PLX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $17.9M | -$1.1M | $-0.01 |
| Q2 2025 | $13.5M | $164.0K | $0.00 |
| Q1 2025 | $3.7M | -$3.6M | $-0.05 |
| Q3 2024 | $10.3M | -$1.9M | $0.03 |
| Q2 2024 | $13.5M | -$2.2M | $-0.03 |
| Q1 2024 | $3.7M | -$3.1M | $-0.05 |
| Q3 2023 | $10.3M | -$1.9M | $-0.04 |
| Q2 2023 | $8.8M | -$5.3M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Protalix BioTherapeutics, Inc. Dividends, Buybacks & Capital Allocation
PLX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Protalix BioTherapeutics, Inc. (CIK: 0001006281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PLX
What is the AI rating for PLX?
Protalix BioTherapeutics, Inc. (PLX) has an AI rating of STRONG SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PLX's key strengths?
Claude: Very low leverage with minimal debt burden (Debt/Equity: 0.02x, only $912K long-term debt). Healthy short-term liquidity ratios (Current: 2.51x, Quick: 1.54x) provide near-term operational flexibility.
What are the risks of investing in PLX?
Claude: Revenue decline of 1.2% YoY in biotech sector indicates failing commercialization and market demand. Catastrophic cash burn: $12M operating outflow annually with only $14.7M cash (approximately 1.2 years runway).
What is PLX's revenue and growth?
Protalix BioTherapeutics, Inc. reported revenue of $52.7M.
Does PLX pay dividends?
Protalix BioTherapeutics, Inc. does not currently pay dividends.
Where can I find PLX SEC filings?
Official SEC filings for Protalix BioTherapeutics, Inc. (CIK: 0001006281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PLX's EPS?
Protalix BioTherapeutics, Inc. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PLX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Protalix BioTherapeutics, Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PLX stock overvalued or undervalued?
Valuation metrics for PLX: ROE of -13.7% (sector avg: 15%), net margin of -12.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PLX stock in 2026?
Our dual AI analysis gives Protalix BioTherapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PLX's free cash flow?
Protalix BioTherapeutics, Inc.'s operating cash flow is $-12.0M, with capital expenditures of $1.6M. FCF margin is -25.8%.
How does PLX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -12.5% (avg: 12%), ROE -13.7% (avg: 15%), current ratio 2.51 (avg: 2).